Ivermectin: Pierre Kory, MD letter to National Institutes of Health

“Guess what I did this weekend? I wrote a letter with my FLCCC colleagues to the NIH Guidelines Panel in response to their recent update of the recommendation for ivermectin to “neutral”. The letter details the many weaknesses in their publicly stated rationale for such a cautious approach. Please share widely:” ~ Pierre Kory

From the letter:

“On January 14, 2021, the NIH upgraded their recommendation and now
considers ivermectin an option for use in COVID-19 —by no longer recommending “against” the use of ivermectin for the treatment of COVID-19. A similar neutral stance applies to monoclonal antibodies and convalescent plasma, both of which are widely used in COVID-19 treatment in the U.S.”

Link to letter:

About budbromley

Bud is a retired life sciences executive. Bud's entrepreneurial leadership exceeded three decades. He was the senior business development, marketing and sales executive at four public corporations, each company a supplier of analytical and life sciences instrumentation, software, consumables and service. Prior to those positions, his 19 year career in Hewlett-Packard Company's Analytical Products Group included worldwide sales and marketing responsibility for Bioscience Products, Global Accounts and the International Olympic Committee, as well as international management assignments based in Japan and Latin America. Bud has visited and worked in more than 65 countries and lived and worked in 3 countries.
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.